Anti-MEK1 (phospho S298) antibody [EPR3338] (ab96379)

Overview

  • Product nameAnti-MEK1 (phospho S298) antibody [EPR3338]
    See all MEK1 primary antibodies
  • Description
    Rabbit monoclonal [EPR3338] to MEK1 (phospho S298)
  • Specificityab96379 detects MEK1 phosphorylated at threonine 298.
  • Tested applicationsSuitable for: ICC/IF, WB, IHC-Frmore details
    Unsuitable for: Flow Cyt or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A phospho specific peptide corresponding to residues surrounding serine 298 of Human MEK1.

  • Positive control
    • WB: HeLa cell lysates IHC-P: colonic carcinoma tissue ICC/IF: HeLa cells
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A trial size is available to purchase for this antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab96379 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/100 - 1/250.
WB 1/1000 - 1/5000. Detects a band of approximately 45 kDa (predicted molecular weight: 43 kDa).
IHC-Fr 1/100 - 1/250.
  • Application notesIs unsuitable for Flow Cyt or IP.
  • Target

    • FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
    • Tissue specificityWidely expressed, with extremely low levels in brain.
    • Involvement in diseaseDefects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
    • Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications
      Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
      Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
    • Information by UniProt
    • Database links
    • Alternative names
      • Dual specificity mitogen activated protein kinase kinase 1 antibody
      • Dual specificity mitogen-activated protein kinase kinase 1 antibody
      • ERK activator kinase 1 antibody
      • MAP kinase kinase 1 antibody
      • MAP kinase/Erk kinase 1 antibody
      • MAP2K1 antibody
      • MAPK/ERK kinase 1 antibody
      • MAPKK 1 antibody
      • MAPKK1 antibody
      • MEK 1 antibody
      • Mek1 antibody
      • MEKK1 antibody
      • Mitogen activated protein kinase kinase 1 antibody
      • MKK 1 antibody
      • MKK1 antibody
      • MP2K1_HUMAN antibody
      • PRKMK1 antibody
      • Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1) antibody
      • Protein kinase mitogen activated, kinase 1 antibody
      see all

    Anti-MEK1 (phospho S298) antibody [EPR3338] images

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (S)-5-Fluorowillardiine (ab120036), by ICC/IF. Increase in expression of MEK1 (phospho S298) correlates with increased concentration of (S)-5-Fluorowillardiine, as described in literature.
      The cells were incubated at 37°C for 6h in media containing different concentrations of ab120036 ((S)-5-Fluorowillardiine) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
    • ab96379 staining MEK1 (phospho S298) in the NIH3T3  cell line from Mouse fibroblasts by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde and blocked with 10% serum for 60 minutes at 24°C. Samples were incubated with primary antibody (1/100) for 16 hours at 4°C. An Alexa Fluor®488-conjugated Donkey anti-rabbit polyclonal(1/500) was used as the secondary antibody.

      See Abreview

    • All lanes : Anti-MEK1 (phospho S298) antibody [EPR3338] (ab96379) at 1/1000 dilution

      Lane 1 : HeLa cell lysates
      Lane 2 : HeLa cell lysates treated with LP

      Lysates/proteins at 10 µg per lane.

      Secondary
      HRP/AP polymerized antibody

      Predicted band size : 43 kDa
      Observed band size : 45 kDa (why is the actual band size different from the predicted?)
    • ab96379, at a 1/100 dilution, staining MEK1 in paraffin embedded Human colonic carcinoma tissue by Immunohistochemical analysis.
    • ab96379, at a 1/100 dilution, staining MEK1 in HeLa cells by Immunofluorescent analysis.
    • ab96379 showing positive staining in Thyroid gland carcinoma tissue.

    • ab96379 showing positive staining in Glioma tissue.

    • ab96379 showing positive staining in Ovarian carcinoma tissue.

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with CNQX (ab120017), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of CNQX, as described in literature.
      The cells were incubated at 37øC for 24h in media containing different concentrations of ab120017 (CNQX) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4øC in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with CNQX disodium salt (ab120044), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of CNQX disodium salt, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120044 (CNQX disodium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with NBQX disodium salt (ab120046), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of NBQX disodium salt, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120046 (NBQX disodium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with DNQX disodium salt (ab120169), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of DNQX disodium salt, as described in literature.
      The cells were incubated at 37°C for 3h in media containing different concentrations of ab120169 (DNQX disodium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (S)-5-Chlorowillardiine (ab120062), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of (S)-5-Chlorowillardiine, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120062 ((S)-5-Chlorowillardiine) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (S)-5-Nitrowillardiine (ab120063), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of (S)-5-Nitrowillardiine, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120063 ((S)-5-Nitrowillardiine) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (R,S)-AMPA (ab120130), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of(R,S)-AMPA, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120130 ((R,S)-AMPA) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (S)-AMPA (ab120005), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of (S)-AMPA, as described in literature.
      The cells were incubated at 37°C for 6h in media containing different concentrations of ab120005 ((S)-AMPA) in water, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with GYKI 52466 (ab120336), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of GYKI 52466, as described in literature.
      The cells were incubated at 37°C for 1h in media containing different concentrations of ab120336 (GYKI 52466) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with NBQX (ab120045), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of NBQX, as described in literature.
      The cells were incubated at 37°C for 1h in media containing different concentrations of ab120045 (NBQX) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with DNQX (ab120018), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of DNQX, as described in literature.
      The cells were incubated at 37°C for 1h in media containing different concentrations of ab120018 (DNQX) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (S)-Williardine (ab120040), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of (S)-Williardine, as described in literature.
      The cells were incubated at 37°C for 6h in media containing different concentrations of ab120040 ((S)-Williardine) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

    References for Anti-MEK1 (phospho S298) antibody [EPR3338] (ab96379)

    ab96379 has not yet been referenced specifically in any publications.

    Product Wall

    Application Immunocytochemistry/ Immunofluorescence
    Sample Human Cell (HuH7 and HT29 tumor cells)
    Specification HuH7 and HT29 tumor cells
    Blocking step Triton-X-100 PBS supplemented with 10% rat serum as blocking agent for 1 hour(s) and 30 minute(s) · Concentration: 0.5%
    Fixative Paraformaldehyde
    Username

    Paul Dent

    Verified customer

    Submitted Feb 16 2015

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Immunocytochemistry/ Immunofluorescence
    Sample Mouse Cell (NIH3T3)
    Specification NIH3T3
    Fixative Paraformaldehyde
    Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 24°C
    Username

    Abcam user community

    Verified customer

    Submitted Mar 22 2013

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Immunocytochemistry/ Immunofluorescence
    Sample Human Cell (HUVEK cells)
    Specification HUVEK cells
    Fixative Paraformaldehyde
    Permeabilization Yes - 0.1% Triton X100
    Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 1% · Temperature: 25°C
    Username

    Abcam user community

    Verified customer

    Submitted Nov 23 2012

    Application Western blot
    Sample Monkey Cell lysate - whole cell (COS1 cell line)
    Loading amount 25 µg
    Specification COS1 cell line
    Gel Running Conditions Reduced Denaturing (12%)
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Username

    Abcam user community

    Verified customer

    Submitted Nov 23 2012

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Western blot
    Sample Mouse Tissue lysate - whole (Mouse embryonic whole lung)
    Loading amount 25 µg
    Specification Mouse embryonic whole lung
    Gel Running Conditions Reduced Denaturing (12%)
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Username

    Abcam user community

    Verified customer

    Submitted Nov 23 2012

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Western blot
    Sample Human Cell lysate - whole cell (HEK293)
    Loading amount 25 µg
    Specification HEK293
    Gel Running Conditions Reduced Denaturing (12%)
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Username

    Abcam user community

    Verified customer

    Submitted Nov 23 2012

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"